CONTEMPLATING THE FULL MEASURE OF PANDEMIC RESPONSE

ABSTRACT

The top contributing factors include * The proactive and accommodating way that regulatory agencies and ethical review committees have supported development planning and activity. * The rapid mobilization of internal and external scientific and operating teams with a singular and common focus. * The fast deployment of remote and virtual technology solutions supported by more open data, information sharing, and advanced analytics. * The execution of parallel clinical trials and the compressed time between clinical trial phases. * The de-risking of development activity through the availability of global funding and resources. * The unusual frequency and extent of global media coverage contributing to unusually high public visibility. Many of the approaches and solutions deployed-such as remote monitoring, e-consent, home nursing visits, and integrated data management platforms-faced significant difficulty replacing legacy approaches before the pandemic. Clinical research data volume has been rising dramatically for decades as protocol design objectives and scope have increased.